Literature DB >> 36214901

The international consensus classification of mastocytosis and related entities.

Roos J Leguit1, Sa A Wang2, Tracy I George3, Alexandar Tzankov4, Attilio Orazi5.   

Abstract

Mastocytosis is a neoplasm characterized by a clonal proliferation of mast cells, which accumulate in one or multiple organs, associated with an extremely heterogeneous clinical presentation. The disease can be limited to the skin (cutaneous mastocytosis) that is mostly seen in childhood and usually behaves in a benign fashion. Adult patients most often present with systemic disease with or without skin lesions. This includes indolent forms such as indolent systemic mastocytosis and its subvariant bone marrow mastocytosis, and smoldering systemic mastocytosis as well as aggressive forms including aggressive systemic mastocytosis, systemic mastocytosis with an associated myeloid neoplasm (previously called systemic mastocytosis with an associated hematologic neoplasm), and mast cell leukemia. In addition, mast cell sarcoma is a rare aggressive form of mastocytosis that can present in the skin as well as at extracutaneous sites. This review article focuses on the updates in mastocytosis of the 2022 international consensus classification (ICC).
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Aggressive mastocytosis; Bone marrow biopsy; ICC; Mast cell leukemia; Mast cell sarcoma; Mastocytosis

Year:  2022        PMID: 36214901     DOI: 10.1007/s00428-022-03423-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  62 in total

1.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis.

Authors:  W R Sperr; L Escribano; J H Jordan; G H Schernthaner; M Kundi; H P Horny; P Valent
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

2.  Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1.

Authors:  Jonathan J Lyons; Jack Chovanec; Michael P O'Connell; Yihui Liu; Julij Šelb; Roberta Zanotti; Yun Bai; Jiwon Kim; Quang T Le; Tom DiMaggio; Lawrence B Schwartz; Hirsh D Komarow; Matija Rijavec; Melody C Carter; Joshua D Milner; Patrizia Bonadonna; Dean D Metcalfe; Peter Korošec
Journal:  J Allergy Clin Immunol       Date:  2020-07-24       Impact factor: 10.793

Review 3.  Paediatric mastocytosis: a systematic review of 1747 cases.

Authors:  C Méni; J Bruneau; S Georgin-Lavialle; L Le Saché de Peufeilhoux; G Damaj; S Hadj-Rabia; S Fraitag; P Dubreuil; O Hermine; C Bodemer
Journal:  Br J Dermatol       Date:  2015-02-08       Impact factor: 9.302

Review 4.  Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.

Authors:  Karin Hartmann; Luis Escribano; Clive Grattan; Knut Brockow; Melody C Carter; Ivan Alvarez-Twose; Almudena Matito; Sigurd Broesby-Olsen; Frank Siebenhaar; Magdalena Lange; Marek Niedoszytko; Mariana Castells; Joanna N G Oude Elberink; Patrizia Bonadonna; Roberta Zanotti; Jason L Hornick; Antonio Torrelo; Jürgen Grabbe; Anja Rabenhorst; Boguslaw Nedoszytko; Joseph H Butterfield; Jason Gotlib; Andreas Reiter; Deepti Radia; Olivier Hermine; Karl Sotlar; Tracy I George; Thomas K Kristensen; Hanneke C Kluin-Nelemans; Selim Yavuz; Hans Hägglund; Wolfgang R Sperr; Lawrence B Schwartz; Massimo Triggiani; Marcus Maurer; Gunnar Nilsson; Hans-Peter Horny; Michel Arock; Alberto Orfao; Dean D Metcalfe; Cem Akin; Peter Valent
Journal:  J Allergy Clin Immunol       Date:  2015-10-21       Impact factor: 10.793

Review 5.  Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.

Authors:  P Valent; K Sotlar; W R Sperr; L Escribano; S Yavuz; A Reiter; T I George; H C Kluin-Nelemans; O Hermine; J H Butterfield; H Hägglund; C Ustun; J L Hornick; M Triggiani; D Radia; C Akin; K Hartmann; J Gotlib; L B Schwartz; S Verstovsek; A Orfao; D D Metcalfe; M Arock; H-P Horny
Journal:  Ann Oncol       Date:  2014-03-27       Impact factor: 32.976

6.  Paediatric mastocytosis: long-term follow-up of 53 patients with whole sequencing of KIT. A prospective study.

Authors:  C Meni; S Georgin-Lavialle; L Le Saché de Peufeilhoux; J P Jais; S Hadj-Rabia; J Bruneau; S Fraitag; K Hanssens; P Dubreuil; O Hermine; C Bodemer
Journal:  Br J Dermatol       Date:  2018-09-09       Impact factor: 9.302

Review 7.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

8.  Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm.

Authors:  Peter Valent
Journal:  J Allergy Clin Immunol Pract       Date:  2022-09

9.  Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.

Authors:  Georg Greiner; Bettina Sprinzl; Aleksandra Górska; Franz Ratzinger; Michael Gurbisz; Nadine Witzeneder; Klaus G Schmetterer; Bettina Gisslinger; Goekhan Uyanik; Emir Hadzijusufovic; Harald Esterbauer; Karoline V Gleixner; Maria T Krauth; Michael Pfeilstöcker; Felix Keil; Heinz Gisslinger; Boguslaw Nedoszytko; Marek Niedoszytko; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

Review 10.  Inherited and acquired determinants of serum tryptase levels in humans.

Authors:  Jonathan J Lyons
Journal:  Ann Allergy Asthma Immunol       Date:  2021-06-24       Impact factor: 6.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.